Insight Innovation: The Risky Bet on the First Cancer Vaccine
Skin cancer could soon be fought using the same principle that was used to tame the coronavirus. Moderna and Merck are reporting success with an mRNA vaccine. However, there are hurdles.
Moderna has announced positive test results for an innovative skin cancer vaccine developed in partnership with Merck & Co. The vaccine, which uses mRNA technology, showed strong results in a large study, marking a potential breakthrough in cancer treatment. The medication could be on the market as early as 2027, with analysts predicting billions in sales. Moderna's CEO, Stéphane Bancel, is leading the company's efforts in this area, following their successful COVID-19 vaccine development.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
